Table 3 Selected additional description of intervention-specific cost parameter details (see Supplementary Material Table S2 for the full details).
Input Parameter | Source | Expected Value and 95% UI | Distri-bution |
|---|---|---|---|
Costs for CVD assessment and being prescribed CVD preventive pharmacotherapy | |||
GP visits for initial CVD risk assessment and on-going prescriptions and check-ups (same for double therapy and single medications) | PHARMAC cost resource manual38 | NZ$218 (in 2011 dollars) per annum over the five year intervention period | Gamma, SD ± 20% |
Fasting lipid test on first consultation (required for all CVD risk assessment, both double therapy and single medications) | HealthTracker data for 2011 | $28.29 (in first year of intervention period only) | Gamma, SD ± 10% |
Two annual prescriptions via telephone from GP (same for double therapy and single medications) | PHARMAC cost resource manual38 | $28.93 per annum (2011 dollars) | Gamma, SD ± 10% |
Pharmacist payments for double therapy (2 medicines at 4 times year) | PHARMAC cost resource manual38 and pricing data for an agreement with community pharmacies39 | $41.57 per annum (2011 dollars) | Gamma, SD ± 10% |
Pharmacist payments for dispensing single medications (1 dispensing 4 times year) | As above | $20.78 per annum | Gamma, SD ± 10% |
Pharmaceuticals | |||
Lipid-lowering medication (same for double therapy and single medications) | PHARMAC Online Schedule in 2017 (https://www.pharmac.govt.nz/Schedule) | $10.97 (2011 dollars) | Gamma, SD ± 10% |
Anti-hypertensive (same for double therapy and single medications) | As above | $6.21 (2011 dollars) | Gamma, SD ± 10% |
Total annual cost of double therapy | See above | $17.18 per annum (2011 dollars) | See for individual medicines |
